Current considerations in AYA Hodgkin lymphoma.
AYA
Hodgkin lymphoma
adolescent
lymphoma
young adult
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
22
11
2018
medline:
19
9
2019
entrez:
22
11
2018
Statut:
ppublish
Résumé
Hodgkin lymphoma (HL) commonly occurs in adolescents and young adults (AYA), defined by the National Cancer Institute as people diagnosed with cancer between the ages of 15 and 39 years. Despite therapeutic advances, the AYA population has derived less incremental benefit compared to both paediatric and adult counterparts. Although the exact aetiology is unclear, contributing factors probably include differences in disease biology, delayed diagnosis, decreased participation in clinical trials and treatment adherence secondary to complex social factors. As such, while HL remains highly curable, there is not a clear consensus regarding the management of patients within this age range, specifically whether paediatric or adult regimens are preferred or how best to incorporate emerging therapeutic advancements. Ongoing clinical trials, as well as continued collaborative efforts are required to address the needs of this population, investigate the potential for unique biological factors and allow for optimization of treatment. Here we review current prognostic and treatment strategies for paediatric and adult patients with HL and highlight complexities around the management of this patient population.
Identifiants
pubmed: 30460695
doi: 10.1111/bjh.15640
pmc: PMC6310106
mid: NIHMS992028
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-81Subventions
Organisme : NCI NIH HHS
ID : L30 CA233859
Pays : United States
Informations de copyright
© 2018 British Society for Haematology and John Wiley & Sons Ltd.
Références
J Clin Oncol. 2007 Jan 20;25(3):332-7
pubmed: 17235049
J Clin Oncol. 2007 Aug 20;25(24):3746-52
pubmed: 17646666
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Clin Oncol. 1988 Aug;6(8):1285-92
pubmed: 3411341
Blood. 2011 Mar 3;117(9):2596-603
pubmed: 21079154
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Blood. 2012 Oct 25;120(17):3530-40
pubmed: 22955918
Cancer Immunol Res. 2016 Nov;4(11):910-916
pubmed: 27737878
J Clin Oncol. 1989 Nov;7(11):1630-6
pubmed: 2809679
JAMA Pediatr. 2016 May 1;170(5):495-501
pubmed: 26999630
Cancer. 2018 Jan 1;124(1):136-144
pubmed: 28902390
Eur J Cancer. 2010 Mar;46(4):765-81
pubmed: 20116997
Acta Oncol. 2017 Feb;56(2):288-294
pubmed: 28077017
J Oncol Pract. 2016 Apr;12(4):e388-95
pubmed: 27026648
Am J Hematol. 2016 Jun;91(4):434-42
pubmed: 27001163
Semin Oncol. 2010 Apr;37(2):e1-8
pubmed: 20494693
Br J Haematol. 2009 Jan;144(1):24-40
pubmed: 19087093
J Clin Oncol. 2006 Jun 1;24(16):2520-6
pubmed: 16735704
Pediatr Blood Cancer. 2017 Apr;64(4):
pubmed: 27786406
J Clin Oncol. 2009 Aug 20;27(24):3901-7
pubmed: 19620485
Lancet Oncol. 2016 Jul;17(7):896-906
pubmed: 27237614
J Clin Oncol. 2002 Sep 15;20(18):3765-71
pubmed: 12228196
N Engl J Med. 2010 Aug 12;363(7):640-52
pubmed: 20818855
Ann Oncol. 2013 Dec;24(12):3070-6
pubmed: 24148816
Blood. 2014 Nov 27;124(23):3373-9
pubmed: 25428219
J Clin Oncol. 2014 Apr 20;32(12):1188-94
pubmed: 24637998
Am J Pathol. 1997 Oct;151(4):1123-30
pubmed: 9327746
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28612375
J Clin Oncol. 2013 Feb 20;31(6):684-91
pubmed: 23182987
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cochrane Database Syst Rev. 2017 May 25;5:CD007941
pubmed: 28541603
Blood. 2018 May 31;131(22):2454-2465
pubmed: 29650799
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Eur J Cancer Care (Engl). 2016 May;25(3):419-27
pubmed: 26239724
N Engl J Med. 2012 Feb 2;366(5):399-408
pubmed: 22149921
Blood. 1989 Jan;73(1):47-56
pubmed: 2462943
J Clin Oncol. 2010 Aug 10;28(23):3680-6
pubmed: 20625128
J Clin Oncol. 2014 Nov 10;32(32):3651-8
pubmed: 25311218
J Clin Oncol. 2009 Nov 10;27(32):5390-6
pubmed: 19738111
Paediatr Child Health. 2006 Feb;11(2):103-6
pubmed: 19030262
Blood. 2009 Sep 3;114(10):2051-9
pubmed: 19584400
J Clin Oncol. 2013 Feb 20;31(6):692-700
pubmed: 23182984
N Engl J Med. 2015 Apr 23;372(17):1598-607
pubmed: 25901426
J Pediatr Hematol Oncol. 2015 Apr;37(3):161-9
pubmed: 25757020
Cancer. 2012 Dec 15;118(24):6179-87
pubmed: 22736071
Blood. 2010 Nov 11;116(19):3724-34
pubmed: 20664057
J Clin Oncol. 2009 Dec 20;27(36):6079-85
pubmed: 19901121
Med Pediatr Oncol. 2002 Jan;38(1):1-10
pubmed: 11835231
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449
J Clin Oncol. 2009 Feb 10;27(5):805-11
pubmed: 19124807
Pediatr Hematol Oncol. 2007 Jul-Aug;24(5):325-36
pubmed: 17613877
Haematologica. 2011 Nov;96(11):1692-9
pubmed: 21828120
J Clin Oncol. 2013 Apr 20;31(12):1562-8
pubmed: 23509321
Blood Adv. 2017 Oct 10;1(22):1945-1958
pubmed: 29296842
Cancer Control. 2016 Oct;23(4):424-433
pubmed: 27842332
Radiat Res. 2005 Jun;163(6):695-6
pubmed: 16044495
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
Blood. 2014 Mar 13;123(11):1658-64
pubmed: 24478403
J Clin Oncol. 2011 Oct 20;29(30):4045-53
pubmed: 21931022
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):264-73
pubmed: 26826029
Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65
pubmed: 22911615